Stem cell-based model suggests deafness treatments
Researchers at Tokyo's Keio University School of Medicine have developed the first in vitro cochlear cell model using patient-derived disease-specific human induced pluripotent stem cells (hiPSCs), which allows study of the pathogenesis of congenital deafness and may lead to its treatment.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST